HRP20211605T1 - Spojeni pentaciklični derivati imidazola - Google Patents
Spojeni pentaciklični derivati imidazola Download PDFInfo
- Publication number
- HRP20211605T1 HRP20211605T1 HRP20211605TT HRP20211605T HRP20211605T1 HR P20211605 T1 HRP20211605 T1 HR P20211605T1 HR P20211605T T HRP20211605T T HR P20211605TT HR P20211605 T HRP20211605 T HR P20211605T HR P20211605 T1 HRP20211605 T1 HR P20211605T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- trifluoromethyl
- halogen
- represents hydrogen
- hydroxy
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 150000001204 N-oxides Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- -1 C1-6Alkoxy Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005215 cycloalkylheteroaryl group Chemical group 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- 230000000771 oncological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (10)
1. Spoj formule (I) ili njegov N-oksid, ili njegova farmaceutski prihvatljiva sol,
[image]
gdje
-X-Q- predstavlja -O-, -O-C(O)-, -O-C(CH-CN)-, -S-, -SO-, -SO2-; ili -N(Rg)-, - N(Rf)-CO-, -N(Rf)-SO2-, -O-CH2-, -CH2-S-, -CH2-SO-, -CH2-SO2-, -N(Rg)-CH2-, -N(Rf)-C(S)-, -N=S(O)(CH3)-, -O-C(=CH2)-ili -S(=N-CN)-, od kojih bilo koja grupa može biti opcionalno supstituirana sa jednim ili više supstituenata izabranih između halogena, (C1-6)alkil, karboksi, trifluorometil, (C2-6)alkilkarbonil, (C2-6)alkoksikarbonil, i hidroksi(C1-6)alkil;
Z predstavlja metilen;
E predstavlja spojeni heteroaromatični sistem prstena izabran između grupa formula (Ea) i (Eb),
[image]
gdje zvjezdica (*) predstavlja mjesto vezivanja E za ostatak molekula;
R1 predstavlja halogen ili cijano; ili aril, heteroaril, (C3-7)cikloalkil-heteroaril, (C3-7)heterocikloalkil-heteroaril, (C4-9)heterobicikloalkil-heteroaril, (C3-7)heterocikloalkil, (C3-7)heterocikloalkenil, ili (C3-7)heterocikloalkenil-aril, od kojih bilo koja grupa može biti opcionalno supstituirana sa jednim, dva ili tri supstituenta izabranih između halogena, cijano, cijano(C1-6)alkil, C1-6 alkil, difluorometil, trifluorometil, hidroksi, (hidroksi)(C1-6)alkil, amino, (amino)(C1-6) alkil, C1-6alkoksi, (C1-6) alkoksi(C1-6)alkil, C2-6 alkilkarbonil, C2-6 alkoksikarbonil, (C2-6) alkoksikarbonil-amino-C1-6 alkil, fosfat(C1-6)alkil, C1-6 alkiltio, C1-6 alkilsulfonil, okso, (C1-6)alkilsulfoksiminil, (C1-6)alkilsulfonil-amino-, di(C1-6)alkilamino (C1-6)alkil, (C2-6)alkilkarbonilamino(C1-6)alkil, di(C1-6)alkenilamino (C1-6)alkil, (C2-6)alkilkarbonilamino(C1-6)alkil, C1-6 alkilsulfonil-amino-C1-6 alkil, tetrahidrofuranil, sulfat (C1-6)alkil, i karboksi-(Ci-6)alkil-karboniloksi-(C1-6 )alkil;
R2 predstavlja vodik ili halogen;
R3 predstavlja vodik ili trifluorometil;
R4 predstavlja vodik ili trifluorometil;
R5 predstavlja halogen, -ORa, difluorometoksi ili trifluorometoksi;
R6 predstavlja vodik, halogen ili trifluorometil;
R7 predstavlja vodik ili trifluorometil;
R8 predstavlja vodik, halogen ili trifluorometil;
R12 predstavlja vodik ili C1-6 alkil;
Ra predstavlja C1-6 alkil;
Rf predstavlja vodik; ili C1-6 alkil, gdje grupa može biti opcionalno supstituirana sa jednim ili više supstituenta izabranih između trifluorometila, karboksi i hidroksi; i
Rg predstavlja vodik; ili C1-6 alkil, -CO-(C1-6)alkil, -SO2-(C1-6)alkil, -CO-(C3-7)heterocikloalkil, -SO2-(C3-7)cikloalkil, - SO2-aril, -SO2-heteroaril, heteroaril ili (C2-6)alkoksikarbonil, od kojih bilo koja grupa može biti opcionalno supstituirana jednim ili više supstituenata izabranih između halogena, C1-6 alkil, karboksi, C1-6 alkoksikarbonil, trifluorometil, C4-9 heterobicikloalkil, (C1-6 alkil)sulfonil, tri(C1-6 alkil)sililoksi, hidroksi i (C1-6)alkoksi.
2. Spoj prema patentnom zahtjevu 1 prikazano formulom (IB) ili (IC), ili njegov N-oksid , ili njegova farmaceutski prihvatljiva sol,
[image]
gdje
Z, -X-Q-, R1, R2, R3, R4, R5, R6, R7, R8, R12, Rg i Rf su kao što je definirano u patentnom zahtjevu 1;
[image]
gdje Z, -X-Q-, R1, R2, R3, R4, R5, R6, R7, R8, R12, Rg i Rf su kao što je definirano u patentnom zahtjevu 1.
3. Spoj prema patentnom zahtjevu 1 u kome -X-Q-predstavlja -O-,-O-C(O)-, -O-C(CH-CN)-, -S-, -SO-, -SO2-, -N(H)-, -N(CO-CH3)-, -N(SO2-CH3)-, -N(CH2-CO-O-CH2-CH3)-, -N[(CO-CH2-(3,7-dioksa-9-azabiciklo[3.3.1]non-9-il)]-, -N[CO-(azetidin-3-il)]-, -N[CO-(metilsulfonil)azetidin-3-il)]-, -N(CH2-COOH)-, -N[(terc-butil)(dimetil)sililoksietil]-, -N(SO2-piridin-3-il)-, -N-(SO2-ciklopropil)-, -N(CH3)-CH2-, -N(CH2-CH2-OH)-, -N(SO2-fenil)-, -N[SO2-(6-metoksi-piridin-3-il)]-, -N(H)-CO-, -N(CH3)-CO-, -N(CH2CH3)-CO-, -N(CH(CH3)2)-CO-, -N(CH2-COOH)-CO-, -N(CH2-CF3)-CO-, -N(CH2-CH2-OH)-CO-, -N(CH2-C(OH)(CH3)2)-CO-, -N(CD3)-CO-, -N(H)-CH2-, -N(CH2-COOH)-CH2-, -N(H)-CH(CF3)-, -N(H)-CH(CH3)-, -N(H)-C(S)-, -N(CO-CH3)-CH(CH3)-, -N(SO2-CH3)-CH2-, -N(CO-CH3)-CH(CH3)-, -N=S(O)(CH3)-, -O-CH(CF3)-, -CH(COOC2H5)-S-, -CH2-SO-, -CH2-SO2-, -CH(C(OH)(CH3)2)-S-, -CH(CH2OH)-S-, -O-C(=CH2)-, -N[S(O)2-(piridin-1H-2-on)]-, -N(H)-SO2-, -N(pirimidinil)-, -N(COOC2H5)-, -S(=N-CN)-ili -N(C2H5)-CO-.
4. Spoj prema patentnom zahtjevu 1 prikazan formulom (IIB) ili njegov N-oksid, ili njegova farmaceutski prihvatljiva sol,
[image]
gdje R1, R2 , R3, R4, R5, R6, R7, R8, i Rf su kao što je definirano u patentnom zahtjevu 1.
5. Spoj prema patentnom zahtjevu 1 prikazano formulom (IIB-A), ili njegov N-oksid, ili njegova farmaceutski prihvatljiva sol,
[image]
gdje
R1 predstavlja aril ili heteroaril, od kojih bilo koja grupa može biti opcionalno supstituirana sa jednim, dva ili tri supstituenta izabranih između halogena, cijano, cijano(C1-6)alkil, C1-6 alkil, difluorometil, trifluorometil, hidroksi, (hidroksi)(C1-6)alkil, amino, (amino)(C1-6) alkil, C1-6 alkoksi, (C1-6) alkoksi(C1-6)alkil, C2-6 alkilkarbonil, C2-6 alkoksikarbonil, (C2-6) alkoksikarbonilamino-C1-6 alkil, fosfat(C1-6)alkil, C1-6 alkiltio, C1-6 alkilsulfonil, okso, (C1-6)alkilsulfoksiminil, (C1-6)alkilsulfonil-amino-, di(C1-6)alkilamino (C1-6)alkil, (C2-6)alkilkarbonilamino(C1-6)alkil, di(C1-6)alkenilamino (C1-6)alkil, (C2-6)alkilkarbonilamino(C1-6)alkil, C1-6 alkilsulfonilamino-C1-6 alkil, tetrahidrofuranil, sulfat(C1-6)alkil, i karboksi-(C1-6)alkil-karboniloksi-(C1-6)alkil;
R2 predstavlja vodik ili halogen;
R5 predstavlja halogen, -ORa, difluorometoksi ili trifluorometoksi;
Ra predstavlja C1-6 alkil; i
Rf predstavlja vodik; ili C1-6 alkil, gdje grupa može biti opcionalno supstituirana sa jednim ili više supstituenta izabranih između trifluorometil, karboksi i hidroksi.
6. Spoj prema patentnom zahtjevu 5 prikazan formulom (IIB-AB-A), njegov N-oksid, ili njegova farmaceutski prihvatljiva sol,
[image]
gdje
R9 predstavlja amino(C1-6)alkil, hidroksi(C1-6)alkil, ili (C1-6) alkoksi(C1-6)alkil;
R10 predstavlja vodik ili C1-6 alkil;
R2, R5 i Rf su kao što je definirano u patentnom zahtjevu 5; i
W predstavlja N ili C-H; i
gdje R9 poželjno predstavlja 2-hidroksi-prop-2-il.
7. Spoj prema patentnom zahtjevu 6 gdje W predstavlja N; i/ili
gdje R10 predstavlja vodik.
8. Spoj formule (I) prema bilo kojem od prethodnih patentnih zahtjeva, ili njegov N-oksid, ili njegova farmaceutski prihvatljiva sol, za upotrebu u terapiji.
9. Spoj formule (I) prema bilo kojem od prethodnih patentnih zahtjeva ili njegov N-oksid, ili njegova farmaceutski prihvatljiva sol, za upotrebu u liječenju i/ili prevenciji upalnog ili autoimunog poremećaja, neurološkog ili neurodegenerativnog poremećaja, boli ili nociceptivnog poremećaja, kardiovaskularnog poremećaja, metaboličkog poremećaja, očnog poremećaja ili onkološkog poremećaja.
10. Farmaceutski sastav koji sadrži spoj formule (I) prema bilo kojem od prethodnih patentnih zahtjeva ili njegov N-oksid, ili njegovu farmaceutski prihvatljivu sol, zajedno sa farmaceutski prihvatljivim nosačem.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14290299 | 2014-10-03 | ||
| EP15162641 | 2015-04-07 | ||
| EP15171036 | 2015-06-08 | ||
| PCT/EP2015/072868 WO2016050975A1 (en) | 2014-10-03 | 2015-10-02 | Fused pentacyclic imidazole derivatives |
| EP15771976.6A EP3201196B1 (en) | 2014-10-03 | 2015-10-02 | Fused pentacyclic imidazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211605T1 true HRP20211605T1 (hr) | 2022-01-21 |
Family
ID=54238452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211605TT HRP20211605T1 (hr) | 2014-10-03 | 2015-10-02 | Spojeni pentaciklični derivati imidazola |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US10202405B2 (hr) |
| EP (1) | EP3201196B1 (hr) |
| JP (1) | JP6629847B2 (hr) |
| KR (1) | KR102442235B1 (hr) |
| CN (1) | CN107108672B (hr) |
| AP (1) | AP2017009809A0 (hr) |
| AU (1) | AU2015326798B2 (hr) |
| BR (1) | BR112017006669B1 (hr) |
| CA (1) | CA2962826C (hr) |
| CL (1) | CL2017000787A1 (hr) |
| CO (1) | CO2017003331A2 (hr) |
| CR (1) | CR20170167A (hr) |
| DK (1) | DK3201196T3 (hr) |
| EA (1) | EA032839B1 (hr) |
| EC (1) | ECSP17027306A (hr) |
| ES (1) | ES2885432T3 (hr) |
| GT (1) | GT201700044A (hr) |
| HR (1) | HRP20211605T1 (hr) |
| HU (1) | HUE056133T2 (hr) |
| IL (1) | IL251147B (hr) |
| LT (1) | LT3201196T (hr) |
| MA (1) | MA40770B1 (hr) |
| MX (1) | MX2017004201A (hr) |
| MY (1) | MY181019A (hr) |
| PE (1) | PE20170693A1 (hr) |
| PH (1) | PH12017500414B1 (hr) |
| PL (1) | PL3201196T3 (hr) |
| RS (1) | RS62423B1 (hr) |
| SG (1) | SG11201701796XA (hr) |
| SI (1) | SI3201196T1 (hr) |
| TN (1) | TN2017000083A1 (hr) |
| TW (1) | TWI719949B (hr) |
| UA (1) | UA120764C2 (hr) |
| UY (1) | UY36341A (hr) |
| WO (1) | WO2016050975A1 (hr) |
| ZA (1) | ZA201701946B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI719949B (zh) * | 2014-10-03 | 2021-03-01 | 比利時商Ｕｃｂ生物製藥公司 | 稠合五環咪唑衍生物 |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| UY36629A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| UY36628A (es) | 2015-04-17 | 2016-11-30 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| CN109219609B (zh) | 2016-04-01 | 2022-02-01 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合六环咪唑衍生物 |
| US10654861B2 (en) | 2016-04-01 | 2020-05-19 | UCB Biopharma SRL | Fused pentacyclic imidazole derivatives as modulators of TNF activity |
| WO2017167996A1 (en) | 2016-04-01 | 2017-10-05 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
| EA201892153A1 (ru) | 2016-04-01 | 2019-04-30 | Юсб Байофарма Спрл | Конденсированные пентациклические производные имидазола в качестве модуляторов активности tnf |
| GB201620948D0 (en) | 2016-12-09 | 2017-01-25 | Ucb Biopharma Sprl | Therapeutic agents |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| CN110461842A (zh) * | 2017-03-15 | 2019-11-15 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
| SI3615534T1 (sl) * | 2017-04-25 | 2022-01-31 | UCB Biopharma SRL | Derivati zlitega pentacikličnega imidazola kot modulatorji delovanja TNF |
| JP7429694B2 (ja) * | 2018-10-24 | 2024-02-08 | ユーシービー バイオファルマ エスアールエル | Ｔｎｆ活性のモジュレータとしての縮合五環式イミダゾール誘導体 |
| CN113683505A (zh) * | 2021-09-29 | 2021-11-23 | 厦门大华本安化工安全研究院有限公司 | 一种含氧代环丁基的羧酸酯类化合物的制备方法 |
| US20240247014A1 (en) * | 2022-11-23 | 2024-07-25 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2024129763A1 (en) * | 2022-12-13 | 2024-06-20 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024148191A1 (en) * | 2023-01-05 | 2024-07-11 | Forward Therapeutics, Inc. | MODULATORS OF TNF-α ACTIVITY |
| WO2024223740A1 (en) | 2023-04-26 | 2024-10-31 | Sanofi | Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0449649A3 (en) | 1990-03-30 | 1992-09-02 | Arizona Board Of Regents, Arizona State University | Antineoplastic quinones and methods of using same |
| FR2832711B1 (fr) | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| BRPI0408477A (pt) | 2003-03-10 | 2006-04-04 | Pfizer | compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| KR101941420B1 (ko) | 2011-06-20 | 2019-01-23 | 스페로 트리넴, 인코포레이티드 | 자이라제 및 토포이소머라제 억제제의 인산에스테르 |
| CN104428293B (zh) * | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
| CN104619709B (zh) * | 2012-07-13 | 2016-11-09 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的咪唑并吡啶衍生物 |
| GB201212513D0 (en) * | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| US9266883B2 (en) | 2013-10-25 | 2016-02-23 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| SI3925607T1 (sl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavki za zdravljenje bolezni, ki jih povzroča regulator transmembranske prevodnosti pri cistični fibrozi |
| TWI719949B (zh) * | 2014-10-03 | 2021-03-01 | 比利時商Ｕｃｂ生物製藥公司 | 稠合五環咪唑衍生物 |
-
2015
- 2015-10-02 TW TW104132631A patent/TWI719949B/zh active
- 2015-10-02 MA MA40770A patent/MA40770B1/fr unknown
- 2015-10-02 MX MX2017004201A patent/MX2017004201A/es unknown
- 2015-10-02 EP EP15771976.6A patent/EP3201196B1/en active Active
- 2015-10-02 CN CN201580053711.8A patent/CN107108672B/zh active Active
- 2015-10-02 HU HUE15771976A patent/HUE056133T2/hu unknown
- 2015-10-02 EA EA201790734A patent/EA032839B1/ru not_active IP Right Cessation
- 2015-10-02 PL PL15771976T patent/PL3201196T3/pl unknown
- 2015-10-02 UY UY0001036341A patent/UY36341A/es not_active Application Discontinuation
- 2015-10-02 ES ES15771976T patent/ES2885432T3/es active Active
- 2015-10-02 CA CA2962826A patent/CA2962826C/en active Active
- 2015-10-02 LT LTEPPCT/EP2015/072868T patent/LT3201196T/lt unknown
- 2015-10-02 SI SI201531711T patent/SI3201196T1/sl unknown
- 2015-10-02 HR HRP20211605TT patent/HRP20211605T1/hr unknown
- 2015-10-02 CR CR20170167A patent/CR20170167A/es unknown
- 2015-10-02 MY MYPI2017701132A patent/MY181019A/en unknown
- 2015-10-02 US US15/513,357 patent/US10202405B2/en active Active
- 2015-10-02 PE PE2017000544A patent/PE20170693A1/es unknown
- 2015-10-02 JP JP2017518131A patent/JP6629847B2/ja active Active
- 2015-10-02 KR KR1020177011958A patent/KR102442235B1/ko active IP Right Grant
- 2015-10-02 AP AP2017009809A patent/AP2017009809A0/en unknown
- 2015-10-02 RS RS20211235A patent/RS62423B1/sr unknown
- 2015-10-02 DK DK15771976.6T patent/DK3201196T3/da active
- 2015-10-02 UA UAA201702002A patent/UA120764C2/uk unknown
- 2015-10-02 SG SG11201701796XA patent/SG11201701796XA/en unknown
- 2015-10-02 TN TN2017000083A patent/TN2017000083A1/en unknown
- 2015-10-02 WO PCT/EP2015/072868 patent/WO2016050975A1/en active Application Filing
- 2015-10-02 BR BR112017006669-6A patent/BR112017006669B1/pt active IP Right Grant
- 2015-10-02 AU AU2015326798A patent/AU2015326798B2/en active Active
-
2017
- 2017-03-06 PH PH12017500414A patent/PH12017500414B1/en unknown
- 2017-03-07 GT GT201700044A patent/GT201700044A/es unknown
- 2017-03-14 IL IL251147A patent/IL251147B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01946A patent/ZA201701946B/en unknown
- 2017-03-31 CL CL2017000787A patent/CL2017000787A1/es unknown
- 2017-04-06 CO CONC2017/0003331A patent/CO2017003331A2/es unknown
- 2017-05-03 EC ECIEPI201727306A patent/ECSP17027306A/es unknown
-
2018
- 2018-12-14 US US16/220,847 patent/US10906919B2/en active Active
-
2020
- 2020-11-24 US US17/102,790 patent/US11912721B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211605T1 (hr) | Spojeni pentaciklični derivati imidazola | |
| HRP20230162T1 (hr) | Heteroarilni inhibitori enzima pde4 | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20200632T1 (hr) | Derivati piridopirazina i naftiridina za liječenje raka | |
| PH12014502886A1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| MX2018003215A (es) | Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2. | |
| WO2013192229A8 (en) | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds | |
| MX2016008110A (es) | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. | |
| HRP20170311T1 (hr) | Novi spojevi pirolopirimidina kao inhibitori protein kinaza | |
| HRP20160273T1 (hr) | Derivati pirazolokinolina kao inhibitori pde9 | |
| MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
| GEP201706774B (en) | Heterocyclyl compounds | |
| WO2014028597A3 (en) | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| WO2012101654A3 (en) | Novel triazine compounds | |
| MD4583B1 (ro) | Piridinone biciclice noi | |
| HRP20201522T1 (hr) | Heteroaromatski nmda receptor modulatori i njihove uporabe | |
| RS52838B (en) | PHENOXIMETHYL HETEROCYCLIC COMPOUNDS | |
| WO2014045162A8 (en) | ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS | |
| AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
| RS54319B1 (en) | [1,2,3] TRIAZOLO [4,5-D] PYRIMIDINE DERIVATIVES AS CANABINOID RECEPTOR AGONISTS 2 | |
| IN2014DN10239A (hr) | ||
| IN2015DN01408A (hr) | ||
| MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. |